These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20225195)

  • 1. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.
    Juergens A; Pels H; Rogowski S; Fliessbach K; Glasmacher A; Engert A; Reiser M; Diehl V; Vogt-Schaden M; Egerer G; Schackert G; Reichmann H; Kroschinsky F; Bode U; Herrlinger U; Linnebank M; Deckert M; Fimmers R; Schmidt-Wolf IG; Schlegel U
    Ann Neurol; 2010 Feb; 67(2):182-9. PubMed ID: 20225195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma.
    Fliessbach K; Urbach H; Helmstaedter C; Pels H; Glasmacher A; Kraus JA; Klockgether T; Schmidt-Wolf I; Schlegel U
    Arch Neurol; 2003 Apr; 60(4):563-8. PubMed ID: 12707070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
    Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
    J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.
    Gavrilovic IT; Hormigo A; Yahalom J; DeAngelis LM; Abrey LE
    J Clin Oncol; 2006 Oct; 24(28):4570-4. PubMed ID: 17008697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study.
    Fliessbach K; Helmstaedter C; Urbach H; Althaus A; Pels H; Linnebank M; Juergens A; Glasmacher A; Schmidt-Wolf IG; Klockgether T; Schlegel U
    Neurology; 2005 Apr; 64(7):1184-8. PubMed ID: 15824344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
    J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
    Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
    J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
    Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
    Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
    O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
    McAllister LD; Doolittle ND; Guastadisegni PE; Kraemer DF; Lacy CA; Crossen JR; Neuwelt EA
    Neurosurgery; 2000 Jan; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
    Omuro AM; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2005 Jan; 64(1):69-74. PubMed ID: 15642906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
    Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International study on low-grade primary central nervous system lymphoma.
    Jahnke K; Korfel A; O'Neill BP; Blay JY; Abrey LE; Martus P; Poortmans PM; Shenkier TN; Batchelor TT; Neuwelt EA; Raizer JJ; Schiff D; Pels H; Herrlinger U; Stein H; Thiel E
    Ann Neurol; 2006 May; 59(5):755-62. PubMed ID: 16586496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.